Premium
A novel low‐profile thin‐film nitinol/silk endograft for treating small vascular diseases
Author(s) -
Shayan Mahdis,
Yang Sungyeun,
Ryu WonHyoung,
Chun Youngjae
Publication year - 2017
Publication title -
journal of biomedical materials research part b: applied biomaterials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.665
H-Index - 108
eISSN - 1552-4981
pISSN - 1552-4973
DOI - 10.1002/jbm.b.33548
Subject(s) - thrombogenicity , materials science , biomedical engineering , polyester , polytetrafluoroethylene , silk , biocompatible material , composite number , thin film , vascular graft , composite material , nanotechnology , surgery , medicine , thrombosis
Since the introduction of various endovascular graft materials such as expanded polytetrafluoroethylene (e‐PTFE) and Dacron ® polyester, they have been rapidly applied in endovascular devices for treating a variety of clinical situations. While present endovascular grafts have been successful in treating large blood vessels, there are still significant challenges and limitations for small and tortuous vessels to their use. Recently, our group has demonstrated the potential to use thin‐film nitinol (TFN) as a novel material to develop endografts used in the treatment of a wide range of small vascular diseases because TFN is ultralow profile (that is, a few micrometers thick), relatively thromboresistant, and superelastic. While TFN has shown superior thromboresistance, its surface endothelialization is not rapid and sufficient. Therefore, our laboratory has been exploring the feasibility of using thin‐film silk as a novel coating for facilitating rapid and confluent endothelial cell growth. The purpose of this study is to fabricate a low‐profile composite endograft using thin layers of nitinol and silk, and to evaluate both thrombogenicity as well as endothelial cell and smooth muscle cell responses. This study also evaluates the functionality of the composite endograft using an in vitro blood circulation model. © 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 575–584, 2017.